Time Is Running Out for Generic Biotech
WASHINGTON — Generic drug makers may fail again this year to get a bill passed that would let them market cheaper versions of biotech drugs, some of the most expensive medicines on the market.
The Senate is expected to vote next week on the one major pharmaceutical bill expected to pass this year, and the odds are growing that the biotech generics issue won't be included.